

CONTINUING MEDICAL EDUCATION

Hepatobiliary Tumor Board - 4/26/2027 – 81297-78579

Date: April 26, 2027

Time: 4:00 PM-5:00 PM

UH Cleveland Medical Center

Pierre Gholam, MD; Naemat Sandhu, MBBS
University Hospitals Cleveland Medical Center, UHMG, University Hospitals

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Identify and apply the principles of quality and safety
- 2 Effectively discuss, diagnose, and prove management strategies of the highest quality of care to their patients with Hepatobiliary cancers
- 3 Design an appropriate plan of management of primary and metastatic Hepatobiliary cancers

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|---------------------|---------------------------------|---|
| Pierre Gholam, MD | Course Director, Faculty | Advisor-Eisai, Inc. Advisor-Genentech, Inc. (Relationship has ended) Advisor-AstraZeneca Honoraria-exelixis (Relationship has ended) - 06/03/2026 |
| Ashley Hepner, CNP | Other Planning Committee Member | Nothing to disclose - 06/01/2026 |
| Naemat Sandhu, MBBS | Course Director, Faculty | Grant or research support-Ultragenyx Pharmaceutical Inc - 05/28/2026 |

PRESENTED BY:

SPONSORED BY:



| | | |
|-----------------|---------------------------------|--|
| Seth Sclair, MD | Other Planning Committee Member | Speakers Bureau-Mallinckrodt, Inc. Honoraria-Guidepoint, Atheneum, Clearview, Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kezar Pharmaceuticals (Relationship has ended) - 06/10/2026 |
|-----------------|---------------------------------|--|